These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 35454848)

  • 1. Emerging Biomarkers for Immunotherapy in Glioblastoma.
    Mensali N; Inderberg EM
    Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers for immunotherapy for treatment of glioblastoma.
    Lynes JP; Nwankwo AK; Sur HP; Sanchez VE; Sarpong KA; Ariyo OI; Dominah GA; Nduom EK
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32474411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers of immunotherapy in glioblastoma.
    Savage WM; Yeary MD; Tang AJ; Sperring CP; Argenziano MG; Adapa AR; Yoh N; Canoll P; Bruce JN
    Neurooncol Pract; 2024 Aug; 11(4):383-394. PubMed ID: 39006524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frontiers in the treatment of glioblastoma: Past, present and emerging.
    Janjua TI; Rewatkar P; Ahmed-Cox A; Saeed I; Mansfeld FM; Kulshreshtha R; Kumeria T; Ziegler DS; Kavallaris M; Mazzieri R; Popat A
    Adv Drug Deliv Rev; 2021 Apr; 171():108-138. PubMed ID: 33486006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours: A systematic review and meta-analysis.
    Zou Y; Hu X; Zheng S; Yang A; Li X; Tang H; Kong Y; Xie X
    EBioMedicine; 2021 Jan; 63():103137. PubMed ID: 33310681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination immunotherapy strategies for glioblastoma.
    Chan HY; Choi J; Jackson C; Lim M
    J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current state of immune checkpoints therapy for glioblastoma.
    Wang H; Yang J; Li X; Zhao H
    Heliyon; 2024 Jan; 10(2):e24729. PubMed ID: 38298707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential.
    Yang T; Kong Z; Ma W
    Hum Vaccin Immunother; 2021 Feb; 17(2):546-553. PubMed ID: 32643507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
    Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
    J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in immunotherapy for the treatment of glioblastoma.
    Tivnan A; Heilinger T; Lavelle EC; Prehn JH
    J Neurooncol; 2017 Jan; 131(1):1-9. PubMed ID: 27743144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy and Epigenetic Pathway Modulation in Glioblastoma Multiforme.
    Chin C; Lunking ES; de la Fuente M; Ayad NG
    Front Oncol; 2018; 8():521. PubMed ID: 30483476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current advances in PD-1/PD-L1 axis-related tumour-infiltrating immune cells and therapeutic regimens in glioblastoma.
    Shu C; Li Q
    Crit Rev Oncol Hematol; 2020 Jul; 151():102965. PubMed ID: 32442903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges and strategies for successful clinical development of immune checkpoint inhibitors in glioblastoma.
    Majd N; de Groot J
    Expert Opin Pharmacother; 2019 Sep; 20(13):1609-1624. PubMed ID: 31264484
    [No Abstract]   [Full Text] [Related]  

  • 14. Advances in Nanotechnology-Based Immunotherapy for Glioblastoma.
    Tang L; Zhang M; Liu C
    Front Immunol; 2022; 13():882257. PubMed ID: 35651605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging therapies for glioblastoma: current state and future directions.
    Rong L; Li N; Zhang Z
    J Exp Clin Cancer Res; 2022 Apr; 41(1):142. PubMed ID: 35428347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy.
    Zhai L; Dey M; Lauing KL; Gritsina G; Kaur R; Lukas RV; Nicholas MK; Rademaker AW; Dostal CR; McCusker RH; Raizer JJ; Parsa AT; Bloch O; Wainwright DA
    J Clin Neurosci; 2015 Dec; 22(12):1964-8. PubMed ID: 26279502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T cell dysfunction in glioblastoma: a barrier and an opportunity for the development of successful immunotherapies.
    Jansen JA; Omuro A; Lucca LE
    Curr Opin Neurol; 2021 Dec; 34(6):827-833. PubMed ID: 34569985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of cellular immunotherapy for patients with glioblastoma.
    Vauleon E; Avril T; Collet B; Mosser J; Quillien V
    Clin Dev Immunol; 2010; 2010():. PubMed ID: 20953324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy for Neuro-oncology.
    Majd NK; Dasgupta PR; de Groot JF
    Adv Exp Med Biol; 2021; 1342():233-258. PubMed ID: 34972967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.